A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function

A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Normal Renal Function and Renal Impairment: A Non-randomized, Open-label, Parallel-Controlled, Single-Dose Study

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with moderate, and severe renal impairment compared to participants with normal renal function.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

24

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Clinical Trials Information Group officer
  • Phone Number: 0311-69085587
  • Email: ctr-contact@cspc.cn

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Recruiting
        • Peking University Third Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged between 18 and 75 years (inclusive) at the time of screening, males or females.
  • Body weight ≥ 45.0 kg for females or ≥ 50.0 kg for males, and body mass index (BMI) between 18.0 and 35.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²).
  • LDL-C ≥ 70 mg/dL (1.8 mmol/L) at the screening visit.
  • Participants of childbearing potential, as well as their partners, must agree to use effective and reliable contraceptive measures from the signing of the informed consent form until at least 6 months after study drug administration.
  • Participants must be able to communicate well with the investigator and be willing and able to comply with all protocol requirements throughout the study.
  • For participants with renal impairment: if lipid-lowering agents (including statins, ezetimibe, fibrates, etc.) have been used prior to screening, the dose must have been stable for at least 4 weeks, or the agent must have been discontinued for at least 2 weeks. During the study period, the dose and frequency of previous lipid-lowering therapy are planned to remain unchanged.
  • For participants with renal impairment: participants must have stable renal function, and the eGFR must meet the corresponding renal function classification criteria for the respective group, i.e.: Moderate renal impairment: 30 mL/min ≤ eGFR < 60 mL/min; Severe renal impairment: 15 mL/min ≤ eGFR < 30 mL/min
  • For participants with renal impairment: physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray, abdominal ultrasound, and other examination results must be judged by the investigator as suitable for participation in this study.
  • For participants with normal renal function: no use of any medication (including over-the-counter supplements and vitamins) within 4 weeks prior to screening.
  • For participants with normal renal function: 90 mL/min ≤ eGFR < 130 mL/min.
  • For participants with normal renal function: physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray, abdominal ultrasound, and other examination results must be normal or show abnormalities without clinical significance.

Exclusion Criteria:

  • History of severe allergic diseases, such as anaphylactic shock, systemic severe urticaria, etc., or a history of allergy to oligonucleotide drugs.

  • Any of the following cardiovascular or cerebrovascular events within 6 months prior to screening: unstable angina, myocardial infarction, transient ischemic attack or cerebrovascular accident (e.g., stroke), coronary artery bypass grafting; or other cardiovascular and cerebrovascular diseases that, in the investigator's assessment, make the participant unsuitable for participation in this clinical trial.

  • Prolonged Fridericia-corrected QT interval (QTcF) on a 12-lead electrocardiogram at screening (QTcF: >450 ms for males, >470 ms for females); or severe cardiac arrhythmias (e.g., recurrent or symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia) that, in the investigator's assessment, make the participant unsuitable for participation in this clinical trial.

  • Prior surgery that may affect drug distribution, metabolism, or excretion (e.g., liver or kidney surgery), or anticipated hospitalization during the study period due to surgery or other reasons.

  • Meeting any of the following at screening:

    1. For participants with renal impairment: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; for participants with normal renal function: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg;
    2. Triglycerides >5.7 mmol/L.
  • For participants with renal impairment: alanine aminotransferase (ALT), aspartate aminotransferase (AST), or gamma-glutamyl transferase (GGT) >2.5 × upper limit of normal (ULN), or total bilirubin >2 × ULN; for participants with normal renal function: ALT, AST, GGT, or total bilirubin >1.5 × ULN.

  • Diagnosis of malignancy within 5 years prior to screening (except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, cervical carcinoma in situ, and ductal carcinoma in situ of the breast).

  • Use of PCSK9 monoclonal antibody drugs or oral PCSK9 inhibitors within 180 days prior to screening; use of Leqvio® or any other RNA-based therapy for lipid-lowering purposes within 2 years prior to screening, including but not limited to siRNA or antisense oligonucleotide therapy.

  • Participation in another clinical trial within 3 months prior to screening (i.e., less than 3 months since the last dose of the investigational product).

  • Average daily smoking of more than 5 cigarettes (or equivalent tobacco in e-cigarettes) within 3 months prior to screening, and/or unwillingness to refrain from using any tobacco products during the study period.

  • Regular alcohol consumption within 6 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol content, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine with 12% alcohol content), and/or inability to abstain from alcohol during the study period, and/or a positive breath alcohol test.

  • History of drug abuse, and/or a positive urine drug screening test.

  • Regular consumption of caffeine exceeding 600 mg per day within 3 months prior to screening (1 cup of coffee contains approximately 100 mg of caffeine, 1 cup of tea contains approximately 30 mg of caffeine, and 1 can of cola contains approximately 20 mg of caffeine), or planned use of caffeine-containing products or medications within 24 hours prior to study drug administration.

  • Blood loss or blood donation exceeding 400 mL within 3 months prior to dosing, and/or platelet donation within 2 weeks prior to dosing.

  • Pregnant or lactating women; female participants of childbearing potential with a serum pregnancy test result exceeding the upper limit of normal at screening; or female participants who had unprotected sexual intercourse within 2 weeks prior to screening.

  • For participants with normal renal function: positive for any of hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody; for participants with renal impairment: positive for HBsAg with detectable HBV-DNA, positive for HCV antibody with detectable HCV-RNA, positive for HIV antibody, or positive for Treponema pallidum antibody, meeting any of the above criteria.

  • Currently receiving renal replacement therapy (including kidney transplantation, hemodialysis, etc.).

  • Presence of urinary incontinence at screening.

  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: SYH2053(normal renal function)

Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Normal renal function is defined as estimate glomerular filtration rate (eGFR) of ≥90 milliliter (mL)/minute (min) and <130 mL/min.

subcutaneous injection

Experimental: SYH2053(moderate renal function)

Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Moderate renal function is defined as eGFR of ≥30 mL/min and <60 mL/min.

subcutaneous injection

Experimental: SYH2053(severe renal function)

Participants will receive a single dose of SYH2053 administered by SC injection on Day 1. Severe renal function is defined as eGFR of ≥15 mL/min and <30 mL/min.

subcutaneous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Maximum observed plasma concentration (Cmax)
Time Frame: Time Frame: Pre-dose and multiple timepoints up to 4 days
Time Frame: Pre-dose and multiple timepoints up to 4 days
Area under the curve of the plasma concentration (AUC)
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Time to reach maximum plasma concentration (Tmax)
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Terminal half-life (t1/2)
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Apparent total clearance (CL/F)
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Apparent volume of distribution (Vz/F)
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-dose
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Fraction excreted (fe) of SYH2053 over 72 hours post-dose
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
Renal clearance (CLr) of SYH2053
Time Frame: Pre-dose and multiple timepoints up to 4 days
Pre-dose and multiple timepoints up to 4 days
The serum Low-density lipoprotein cholesterol (LDL-C) level
Time Frame: through study completion, an average of 6 months
through study completion, an average of 6 months
The serum PCSK9 level
Time Frame: through study completion, an average of 6 months
through study completion, an average of 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2026

Primary Completion (Estimated)

July 15, 2027

Study Completion (Estimated)

September 15, 2027

Study Registration Dates

First Submitted

July 2, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe